Dr. Telen is recognized as an expert in the biochemistry and molecular genetics of blood group antigens and the pathophysiological mechanisms of vaso-occlusion in sickle cell disease. She is the Director of the Duke Comprehensive Sickle Cell Center.
Dr. Telen's laboratory focuses on structure/function analysis of membrane proteins expressed by erythroid cells, as well as the role of these proteins in non-erythroid cells. Proteins are also studied in transfectant systems, and research focuses especially on adhesion receptors. The goals of this work are (1) to understand the mechanism and role of red cell adhesion to leukocytes and endothelium in sickle cell disease; (2) to understand the signaling mechanisms leading to activation (and inactivation) of red cell adhesion molecules; (3) to understand the molecular basis of blood group antigen expression, and (4) to understand the interactions of erythroid membrane proteins with other cells and with extracellular matrix..
Recent investigations have focused on the role of signaling pathways in the upregulation of sickle red cell adhesion. Present studies include (1) investigation of beta-adrenergic signaling pathway responsible for activation of B-CAM/LU and LW adhesion receptors; (2) understanding how nitric oxide and ATP downregulate sickle red cell adhesion; (3) studying the effect of these processes in animal models.
Dr. Telen is also involved in a large multicenter study looking for genetic polymorphisms that affect clinical outcomes in sickle cell disease, as well as a multi-center study investigating the mechanisms and treatment of pulmonary hypertension in sickle cell disease.
Sickle cell disease
Education and Training
- M.D., New York University, 1977
- Transfusion Medicine and Hematology
- Role of RBC Reactive Oxygen Species and Their Vicious Cycle in Sickle Vasculopathy
- Multi-site Clinical Laboratory Testing for SickleScan
- Transcriptomic, therapeutic and genetic investigations of sickle cell nephropathy
- AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF RIVIPANSEL (GMI-1070) IN THE TREATMENT OF ONE OR MORE VASOOCCLUSIVE CRISES IN HOSPITALIZED SUBJECTS WITH SICKLE CELL DISEASE.
- CSA - Pfizer 212511 B5201002 Phase 3 Randomized Multicenter Trial
- High-throughput Metabolite Profiling and Genetic Analyses
- Thalassemia Screening in Myanmese and Lao Migrants in Thailand
- Vanderbilt-Emory-Cornell-Duke Consortium for Global Health Fellows (VECDor)
- Factor XIII and Fibrinogen: Mechanisms of Genetic Risk in SCD-Related Priapism
- Use of Mobile Technology to Improve Acute Care Utilization in Sickle Cell Disease
- Duke-UNC Clinical Hematology and Transfusion Research Career Development Program